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ABSTRACT Apolipoprotein E (apoE) mediates the redis-
tribution of lipids among cells and is expressed at highest levels
in brain and liver. Human apoE exists in three major isoforms
encoded by distinct alleles («2, «3, and «4). Compared with APOE
«2 and «3, APOE «4 increases the risk of cognitive impairments,
lowers the age of onset of Alzheimer’s disease (AD), and de-
creases the response to AD treatments. Besides age, inheritance
of the APOE «4 allele is the most important known risk factor for
the development of sporadic AD, the most common form of this
illness. Although numerous hypotheses have been advanced, it
remains unclear how APOE «4 might affect cognition and
increase AD risk. To assess the effects of distinct human apoE
isoforms on the brain, we have used the neuron-specific enolase
(NSE) promoter to express human apoE3 or apoE4 at similar
levels in neurons of transgenic mice lacking endogenous mouse
apoE. Compared with NSE-apoE3 mice and wild-type controls,
NSE-apoE4 mice showed impairments in learning a water maze
task and in vertical exploratory behavior that increased with age
and were seen primarily in females. These findings demonstrate
that human apoE isoforms have differential effects on brain
function in vivo and that the susceptibility to apoE4-induced
deficits is critically influenced by age and gender. These results
could be pertinent to cognitive impairments observed in human
APOE «4 carriers. NSE-apoE mice and similar models may
facilitate the preclinical assessment of treatments for apoE-
related cognitive deficits.
Apolipoprotein E (apoE) functions as an important carrier
protein in the redistribution of lipids among cells (1). The brain
is second only to the liver with respect to apoE expression levels,
and evidence has been accumulating rapidly that apoE plays a
critical role in central nervous system (CNS) integrity, function,
and repair after injury (2–5). Human apoE exists in three major
isoforms (E2, E3, and E4) encoded by three APOE alleles («2, «3,
and «4). The APOE «4 allele is the main known genetic risk factor
for the most common form of Alzheimer’s disease (AD), whereas
the more frequent «3 allele and very rare «2 allele provide relative
protection from this illness (6). In addition, apoE4 has been
related to reduced cognitive function in people without frank
dementia (7, 8). Despite these provocative associations, it remains
unknown how APOE genotype affects CNS function.
The potential physiological importance of murine apoE has
been assessed by comparison of wild-type mice with ApoE
knockout mice (9). Although ApoE knockout mice showed no
obvious abnormalities in CNS development, neurodegenerative
alterations became detectable in their brains at 5–6 months of age
(10). These mice also had diminished regenerative capacity after
perforant pathway lesions (11) and spatial learning deficits (12–
14).
The expression of human apoE isoforms in neurons may be
relevant to AD. In wild-type rodent brains, apoE is detected
primarily in astrocytes, whereas in human brains it is detected in
both astrocytes and neurons (15–17). Striking increases in neu-
ronal immunostaining for apoE have been documented after
CNS injuries in humans and rodents (18, 19). We hypothesized
that impaired cognitive performance and increased risk for AD
in APOE «4 carriers could be caused by effects exerted by apoE4
within neurons. To test this hypothesis, we investigated the
behavioral effects of neuronal expression of human apoE3 or
apoE4 at similar levels in ApoE knockout mice.
MATERIALS AND METHODS
Transgenic Mice. Neuron-specific enolase (NSE)-apoE3 and
NSE-apoE4 transgenes, constructed as described (20), were
microinjected individually into ICR one-cell embryos by standard
procedures. Twenty-one transgenic founder mice (9 NSE-apoE3
and 12 NSE-apoE4) were identified by Southern blot analysis.
NSE-apoE3 and NSE-apoE4 lines with similar levels of human
apoE expression in the brain and cerebrospinal fluid were
identified by RNase protection assay and Western blot analysis
(21). These lines were crossed with ApoE knockout mice (9)
obtained from N. Maeda (University of North Carolina, Chapel
Hill). After elimination of wild-type murine ApoE alleles in two
generations of breedings among the resulting offspring, trans-
genic mice were crossed with ApoE knockout mice (C57BLy6J-
Apoetm1Unc) from The Jackson Laboratories to generate NSE-
apoE3 and NSE-apoE4 mice. These crosses also yielded non-
transgenic ApoE knockout littermates. Behavioral testing (see
below) revealed no significant differences between female ApoE
knockout mice derived from the NSE-apoE4 line (n 5 6) and age-
and sex-matched ApoE knockout mice derived from the NSE-
apoE3 line (n 5 8) or obtained from The Jackson Laboratories
(C57BLy6J-Apoetm1Unc) (n 5 8) (data not shown). Therefore,
these three cohorts were combined (as ‘‘knockout mice’’) in our
statistical analyses. Nontransgenic C57BLy6J mice (from The
Jackson Laboratories) served as wild-type controls.
All NSE-apoE mice used in this study were heterozygous for
the NSE-apoE transgene on a homozygous ApoE knockout
background. The genotype of transgenic and nontransgenic mice
was confirmed by Southern blot analysis of genomic tail DNA by
using a DNA probe for human APOE (20) and by slot blot
analysis using as probe templates the apoE3 or apoE4 minigene
isolated from the transgene constructs. NSE-apoE3 and NSE-
The publication costs of this article were defrayed in part by page charge
payment. This article must therefore be hereby marked ‘‘advertisement’’ in
accordance with 18 U.S.C. §1734 solely to indicate this fact.
© 1998 by The National Academy of Sciences 0027-8424y98y9510914-6$2.00y0
PNAS is available online at www.pnas.org.
This paper was submitted directly (Track II) to the Proceedings office.
Abbreviations: apoE, apolipoprotein E; CNS, central nervous system;
AD, Alzheimer’s disease; NSE, neuron-specific enolase.
‡To whom reprint requests should be addressed at: Gladstone Institute
of Neurological Disease, P.O. Box 419100, San Francisco, CA 94141-
9100. e-mail: jraber@gladstone.ucsf.edu.
iPresent address: Institute of Pharmacological Sciences, University of
Milan, 20133 Milan, Italy.
10914
apoE4 mice were differentiated by PCR. Inclusion of the human
APOE intron 3 in the NSE-apoE4 but not in the NSE-apoE3
construct did not affect transgene expression but allowed differ-
entiation of NSE-apoE3 from NSE-apoE4 mice by PCR: the
amplicon generated with intron 3—spanning primers (forward
primer, nt 3158–3175; reverse primer, nt 3815–3834; GenBank
accession number M10065) was 670 bp in NSE-apoE4 mice and
100 bp in NSE-apoE3 mice. The ApoE knockout status of the
mice was also confirmed by PCR with mouse ApoE-specific
primers (forward primer, nt 2389–2413; reverse primer, nt 2833–
2856; GenBank accession number D00466) and a neomycin-
specific primer (reverse primer, nt 2016–2038 of pSV2.neo plas-
mid; GenBank accession number U02434). This primer combi-
nation generates a 221-bp amplicon for homozygous ApoE
knockout mice and a 467-bp amplicon for wild-type mice (22).
For all PCRs, proteinase K-digested tail tissue (2 ml, 1:100) was
subjected to the touchdown PCR procedure (23) in a total
reaction volume of 22 ml with 0.2 mM of each primer, dNTPs
(dATP, dCTP, dGTP, dTTP, 200 mM each), and 0.15 ml of
AmpliTaq GoldR DNA polymerase (Perkin–Elmer). The PCR
was run on a GeneAmp PCR System 9600 (Perkin–Elmer)
thermocycler, and the products were analyzed on 1.5% agarose
gels.
Behavioral Testing. To minimize the effects of social influ-
ences on behavior, mice were housed individually under condi-
tions of constant temperature (18°C), light from 6:00 a.m. to 6:00
p.m., and free access to food and water. Mice that were analyzed
in all three behavioral paradigms (n 5 162) were tested first in the
open field, then in the water maze, and last in the passive
avoidance test (see below) to minimize the effect of stress on
behavioral results. Before each assessment of mice in the open
field, rotorod, or passive avoidance tests, the equipment was
cleaned with 1 mM acetic acid to remove odors.
Open field activity. Mice were placed individually into brightly
lit automated activity cages equipped with rows of infrared
photocells interfaced with a computer (San Diego Instruments,
San Diego, CA). After a 1-min adaptation period, open field
activity was recorded during three consecutive 10-min periods.
Recorded beam breaks were used to calculate active times, path
lengths, and the number and duration of rearing events (raising
of both forefeet off the ground and extension of the body).
Rotorod test. Mice were evaluated for motor deficits with the
rotorod test (San Diego Instruments). After a 1-min adapta-
tion period on the rod at rest, the rod was accelerated by 5 rpm
every 15 sec, and the length of time mice remained on the rod
(fall latency) recorded.
Water maze test. The ability of mice to locate a hidden platform
submerged in a pool (61 cm in diameter) filled with opaque water
(24°C) was tested in two blocks (separated by a 2-h interval) per
day for 4 days. Each block consisted of two consecutive trials. The
platform location was changed daily, and the starting point at
which the mouse was placed into the water was changed for each
trial. Mice that failed to find the platform within 120 sec were put
on it for 15 sec. On day 5, the ability of the mice to locate a clearly
visible platform was tested to exclude differences in vision, swim
speed, and motivation. Because the time required to reach the
hidden platform (latency) depends on path length as well as swim
speed, all three parameters were recorded with an EthoVision
video tracking system (Noldus Instruments, Sterling, VA) set to
analyze two images per second. Because swim speeds did not
differ significantly among age- and sex-matched mice of the
different genotypes analyzed in this study, latencies were used
here to illustrate differences in water maze performance.
FIG. 1. Immunocytochemical detec-
tion of human apoE in neurons of NSE-
apoE3 and NSE-apoE4 mice and a hu-
man with AD. (A–I) Immunoperoxidase
staining for human apoE revealed wide-
spread neuronal labeling, including neo-
cortex (A–C), hippocampal CA1 region
(D–F), and dentate gyrus (G–I), in NSE-
apoE3 (A, D, and G) and NSE-apoE4
(B, E, and H) mice. No apoE labeling
was seen in corresponding brain regions
of a knockout control lacking NSE-
apoE transgenes (C, F, and I). (J–L)
Immunofluorescence staining for hu-
man apoE strongly labeled neocortical
neurons in NSE-apoE3 (J) and NSE-
apoE4 (H) mice, and in a human AD
case (APOE «3y«4) (L). (Bars: A–I, 160
mm; J–L, 10 mm.)
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Passive avoidance. Passive avoidance learning was measured
with a step-through box (San Diego Instruments) consisting of
a brightly lit compartment and a dark compartment connected
with a sliding door. Mice were placed individually in the bright
compartment. When the mouse entered the dark compart-
ment, the sliding door was closed, and the mouse received a
slight foot shock (0.3 mA, 1 sec). Twenty-four hours later, the
mouse was again placed into the bright compartment, and the
latency in re-entering the dark compartment was recorded up
to 300 sec (criterion).
Immunohistochemistry. Mice were anesthetized with chloral
hydrate and flush-perfused transcardially with 0.9% saline.
Brains were postfixed in phosphate-buffered (pH 7.4) 4% para-
formaldehyde at 4°C for 48 h before vibratome sectioning at 40
mm. Endogenous peroxidase activity was quenched by incubation
in 0.3% H2O2 in PBS for 20 min. Sections were pretreated for 4
min in 1 mgyml proteinase K in a buffer containing 250 mM NaCl,
25 mM EDTA, and 50 mM TriszHCl (pH 8) to facilitate pene-
tration of antibodies. They were next incubated for 1 h with 15%
normal donkey serum (Jackson ImmunoResearch) in PBS and
then for 1 h with polyclonal goat anti-human apoE (Calbiochem),
diluted 1:4,000 (immunofluorescent staining) or 1:10,000 (immu-
noperoxidase staining) in PBS. Sections were then washed twice
in PBS and incubated for 1 h with fluorescein isothiocyanate-
labeled (Jackson ImmunoResearch) or biotin-labeled (Vector
Laboratories) anti-goat to detect antigen-bound anti-human
apoE. After three washes in PBS, immunofluorescently labeled
sections were mounted in VectaShield (Vector Laboratories) and
viewed with a MRC-1024 laser scanning confocal microscope
(Bio-Rad) mounted on an Optiphot-2 microscope (Nikon). For
immunoperoxidase staining, secondary antibody binding was
detected with the ABC-Elite kit (Vector Laboratories).
Statistical Analysis. Data were analyzed with SuperANOVA
(Abacus Concepts, Berkeley, CA). The statistical significance of
differences among means was assessed by ANOVA and, as
indicated, by Dunnett’s or Tukey–Kramer posthoc tests. Learning
curves for the water maze test were compared by repeated-
measures ANOVA using contrasts to assess differences between
specific groups of mice. The null hypothesis was rejected at the
0.05 level.
RESULTS AND DISCUSSION
Comparable Expression of ApoE3 or ApoE4 in Brains of
NSE-apoE Transgenic Mice. The NSE promoter (24) was used to
express minigenes encoding human apoE3 or apoE4 (20) in the
brains of transgenic mice lacking murine apoE (21). For behav-
ioral analysis, two lines of NSE-apoE mice were selected that
showed similar cerebral levels of apoE3 or apoE4 by RNase
protection assay and Western blot analysis (21). To ensure that
potential behavioral differences between these lines reflect dif-
ferences in the biological activity of these apoE isoforms rather
than differences in transgene expression patterns, we used anti-
bodies that recognize both apoE3 and apoE4 to map the distri-
bution of human apoE. Both lines showed a similar widespread
neuronal expression of human apoE immunoreactivity, most
prominently in the neocortex and hippocampus (Fig. 1).
Differential Effects of ApoE3 and ApoE4 on Acquisition of a
Water Maze Task. The ability to remember and process spatial
information, which is impaired in humans with AD (25), can be
tested readily in mice. Various versions of the Morris water maze
test (26) have been used to reveal behavioral deficits in mouse
models (12–14, 27–29). Our version of this test was based on pilot
experiments which showed that it was sensitive to the in vivo CNS
effects of apoE3 and apoE4. The target platform was hidden
under the surface of opaque water, the location at which mice
entered the pool was changed between trials, and the platform
location was changed between days. Mice were tested in four trials
per day on four consecutive days. Trials were divided into two
sessions (blocks) of two consecutive trials with 2 h between
blocks. To find the platform, mice must relate their position in the
pool to constant extramaze cues and quickly store, retrieve, and
utilize information on where the platform is located and where it
is not. Day-to-day improvements likely reflect a combination of
general task learning and consolidated memory for constant
FIG. 2. Differential effects of human apoE3 and apoE4 on water maze
performance in 6-month-old female mice. The time required to locate a
hidden platform submerged in a pool of water (latency) was compared
among wild-type (n 5 16), knockout (n 5 16), NSE-apoE3 (n 5 6), and
NSE-apoE4 (n 5 8) mice. Mice were tested on 4 consecutive days in two
sessions (blocks) per day with a 2-h interval between blocks. The average
latency recorded for each mouse in two successive trials per block was
used to calculate group means 6 SEM. Mice that failed to locate the
platform were assigned a latency value of 120 sec. For block 1 (A),
repeated-measures ANOVA revealed highly significant differences in
day-to-day learning capacities among genotypes (P 5 0.001), specifically
between NSE-apoE4 and NSE-apoE3 (P 5 0.0001), NSE-apoE4 and
wild-type (P 5 0.0001), and knockout and wild-type (P 5 0.02) mice.
Comparison of genotypes on individual days by Tukey–Kramer posthoc
test revealed significant differences between NSE-apoE4 and NSE-apoE3
on day 1 (P , 0.05) and between NSE-apoE4 and all other genotypes on
day 2 (P , 0.01). For block 2 (B), differences in day-to-day learning
capacities among genotypes were even more significant (P 5 0.0008 by
repeated-measures ANOVA), specifically between NSE-apoE4 and
NSE-apoE3 (P 5 0.0002), NSE-apoE4 and wild-type (P 5 0.0006), and
NSE-apoE4 and knockout (P 5 0.018) mice. Comparison of genotypes on
individual days by Tukey–Kramer posthoc test revealed that NSE-apoE4
differed significantly from NSE-apoE3 (P , 0.01) and wild-type (P ,
0.05) mice on day 1 and from all other genotypes on day 2 (P , 0.01).
There were also significant differences in learning curves on day 1 (C). In
contrast to NSE-apoE3 mice, NSE-apoE4 mice did not improve signif-
icantly in their ability to locate the platform over the different trials on day
1, even though the platform was kept in the same location. Differences
among groups similar to those described above for latencies were also
observed for path lengths (data not shown).
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extramaze cues, which should facilitate the development of more
efficient search strategies.
Epidemiological studies in humans suggest that apoE4 inter-
acts with female gender to increase the risk of AD and decrease
responsiveness to treatment (6, 30). Therefore, we first tested four
groups of 6-month-old female mice: NSE-apoE3 and NSE-apoE4
mice, their nontransgenic ApoE knockout littermates, and wild-
type mice (Fig. 2). NSE-apoE4 mice showed striking impairments
in learning the water maze task. In contrast, NSE-apoE3 mice
performed as well as, if not better than, wild-type mice. On day
2, none of eight NSE-apoE4 mice tested located the platform in
the first trial of block 1, and only half of them found it in the first
trial of block 2, whereas five of six NSE-apoE3 mice found the
platform in the first trial of block 1, and all six found it in the first
trial of block 2. Decreases in learning capacity of knockout mice
below wild-type levels were subtler than those in NSE-apoE4
mice, and the difference was statistically significant only in block
1 (Fig. 2). The learning impairment of NSE-apoE4 mice was also
evident when the water maze performance was compared across
the four successive trials of day 1: wild-type, knockout, and
NSE-apoE3 mice showed significant improvements (P 5 0.001),
whereas NSE-apoE4 mice did not. These data suggest that
apoE4, but not apoE3, induces significant impairments in spatial
learning and memory.
Water maze performance can also be influenced by nonspatial
cognitive deficits, such as reduced adaptability to new situations,
as well as by emotional and motor peculiarities such as unusual
swim patterns and passive floating (29). Reduced adaptive be-
havior may well have contributed to the poor performance of
6-month-old female NSE-apoE4 mice over different days. How-
ever, these mice showed no improvement over the four trials on
day 1, even though the platform location remained constant.
Therefore, reduced adaptability alone is not likely to account for
their impaired performance. Moreover, all four groups of mice
swam continuously at similar speeds (Table 1) and in similar
patterns, and there were no significant periods of passive floating,
possibly because the water temperature was low enough (24°C) to
maintain escape motivation. On day 5 of the training cycle, the
ability of the mice to locate a clearly visible platform was tested
to exclude basic deficits in vision, motivation, motor strength, or
coordination. No significant differences in time to locate the
platform were identified (Table 1).
To establish that the differences in water maze performance
were not caused by differences in genetic background, we com-
pared the water maze performance of 6-month-old female non-
transgenic ApoE knockout controls obtained from the NSE-
apoE4 (n 5 6) or NSE-apoE3 (n 5 8) lines or from The Jackson
Laboratories (C57BLy6J-Apoetm1Unc) (n 5 8). No significant
differences in water maze performance were identified (data not
shown). Therefore, potential minor differences in background
genes did not account for the significant behavioral differences
between NSE-apoE3 and NSE-apoE4 transgenic mice.
Dependence of Detrimental ApoE4 Effects on Age and Gender.
Because age is an important risk factor for the development of
AD, we next assessed the effect of age on apoE4-induced
impairments in spatial learning and memory. Comparison of
3-month-old female wild-type, knockout, NSE-apoE3, and NSE-
apoE4 mice in the water maze revealed no significant differences
among groups in block 1 and only subtle impairments in NSE-
apoE4 and knockout mice in block 2 (Fig. 3). These results
indicate that the detrimental functional effects of apoE4 de-
scribed above are strongly dependent on age.
Next, we tested the performance of 6-month-old male wild-
type, knockout, NSE-apoE3, and NSE-apoE4 mice in the water
maze. In contrast to the results in 6-month-old female mice, there
were no significant differences among these groups of males (data
not shown). Other cohorts of male ApoE knockout mice have
shown small (12) or severe (13) learning deficits compared with
wild-type controls. Differences in mouse strains, environmental
factors such as diets, and water maze tests may have contributed
to these divergent findings (31).
Day-to-day learning capacity in the water maze test differed
significantly between 6-month-old males and females in the
NSE-apoE4 (P 5 0.0001, for Blocks 1 and 2) and knockout
groups (P 5 0.013 for block 1, P 5 0.0006 for block 2), but not
in the NSE-apoE3 and wild-type groups. The gender effect is
FIG. 3. Water maze performance of young mice is independent of
cerebral apoE expression. Three-month-old female wild-type (n 5 6),
knockout (n 5 19), NSE-apoE3 (n 5 5), and NSE-apoE4 (n 5 7) mice
were compared in the water maze as described in Fig. 2. In block 1 (A),
mice of all genotypes learned the task without significant differences
identified among groups by repeated-measures ANOVA. In block 2
(B), significant day-to-day improvements were seen only in wild-type
(p 5 0.008) and NSE-apoE3 (p 5 0.001) mice, but not in knockout or
NSE-apoE4 mice. However, the differences in learning curves among
groups in block 2 were not significant by repeated-measures ANOVA.
The average swim speeds among groups of mice did not differ
significantly, and the four groups showed similar performance in
locating the visible platform on day 5 (data not shown).
Table 1. Basic visual and motor skills of 6-month-old female mice
Mice
Latency to reach
visible platform,† sec
Swim speed,‡
cmysec
Rotorod
fall latency, sec
Wild-type 18 6 3 (n 5 16) 15 6 4 (n 5 16) 39 6 3 (n 5 4)
ApoE knockout 18 6 4 (n 5 16) 20 6 4 (n 5 16) 54 6 7 (n 5 14)
NSE–apoE3 16 6 8 (n 5 6) 19 6 8 (n 5 6) 106 6 19 (n 5 6)*
NSE–apoE4 16 6 7 (n 5 8) 18 6 4 (n 5 8) 68 6 12 (n 5 9)
Data represent group means 6 SEM; n indicates number of mice.
*P , 0.001 versus wild-type, P , 0.05 versus knockout (by Tukey–Kramer posthoc test).
†Determined on day 5 of the water maze test.
‡Group means were calculated from average swim speeds of individual mice recorded in 16 trials.
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illustrated for the second day of testing (Fig. 4). These results
indicate that female gender significantly increases the suscepti-
bility to apoE-dependent impairments in spatial learning. This
finding may seem at odds with the beneficial effects estrogens
may have on cognitive impairments in AD (32). However,
although estrogen enhances verbal memory skills, it does not
improve performance in visual-spatial memory tasks (33). In fact,
lower estrogen levels may enhance spatial cognitive performance
in humans (34).
No ApoE Effects on Passive Avoidance Learning. We next
assessed whether apoE also affects learning in a test that is largely
independent of spatial abilities. Unconditioned mice placed into
the bright side of a ‘‘step-through box’’ quickly enter the dark
compartment. In contrast, mice that have been negatively con-
ditioned (by receiving a mild foot shock after entering the dark
compartment for the first time) hesitate to re-enter the dark
compartment when tested 24 h later. This latency in re-entering
the dark compartment is used as a measure of passive avoidance
learning. Testing of 6-month-old female mice (6–16 micey
genotype) showed no significant differences in re-entrance laten-
cies among wild-type (212 6 32 sec), knockout (215 6 28 sec),
NSE-apoE3 (201 6 39 sec), and NSE-apoE4 (261 6 20 sec) mice.
Similarly, age-matched male mice showed no significant differ-
ences in re-entrance latencies; however, fewer males than females
re-entered the dark compartment (data not shown), as previously
reported for nontransgenic rodents (35). The finding that apoE4
significantly impaired learning in the water maze but not in the
step-through box suggests that apoE4 affects spatial learning
more strongly than passive avoidance learning. However, we
cannot exclude the possibility that differences in the overall
complexity and sensitivity of the two behavioral paradigms
contributed to the divergent findings.
Isoform-Specific ApoE Effects on Vertical Exploratory Activ-
ity. To exclude differences in overall activity that could influence
performance on learning tests, we also measured active times and
path lengths of the four groups of mice in the open field test (Fig.
5). Only subtle differences were detected in active times, and no
differences in path lengths. Thus, differences in overall activity
levels do not explain the differences in water maze performance.
There was a striking discrepancy between horizontal and vertical
exploratory activity. Although path lengths did not differ among
groups, NSE-apoE4 and knockout mice, but not NSE-apoE3
mice, had significantly fewer rearing events and shorter rearing
times than wild-type controls.
Reductions in rearing could reflect impairment of vertical
exploratory activity. However, a loss of balance control would
also reduce the duration andyor frequency of rearing because the
two-legged stance used for rearing is less stable than the four-
legged stance used for horizontal movement. Control of body
position involves the vestibular part of the inner ear, propriore-
ceptors in joints and muscles, as well as vision. Six-month-old
NSE-apoE4 mice and knockout controls performed normally in
tests of vestibular function, including the reaching response (36),
air righting reflex (37), and swim patterns (38) (data not shown).
In addition, NSE-apoE4 and knockout mice showed no impair-
ments in the rotorod test compared with wild-type controls
(Table 1). Knockout controls from the NSE-apoE3 (n 5 8) and
NSE-apoE4 (n 5 6) lines did not differ significantly in rotorod
performance (data not shown), indicating that these two lines are
well matched with respect to background genes. The superior
performance of NSE-apoE3 mice in the rotorod test (Table 1)
FIG. 4. Gender dependence of apoE effects on water maze per-
formance in 6-month-old mice. Wild-type (21 males, 16 females),
knockout (14 males, 16 females), NSE-apoE3 (14 males, 6 females),
and NSE-apoE4 (13 males, 8 females) mice were compared in the
water maze as described in Fig. 2. Data represent results obtained in
block 1 (A) and block 2 (B) on the second day of testing. For each of
these blocks, two-factor ANOVA revealed highly significant effects of
genotype and gender (P 5 0.0001) as well as a highly significant
interaction between the effects of genotype and gender (P 5 0.0001).
Significant differences between males and females were identified only
in knockout and NSE-apoE4 mice (P 5 0.0001) but not in wild-type
or NSE-apoE3 mice. Average swim speeds and ability to locate a
visible platform on day 5 did not differ significantly between age-
matched male and female mice (data not shown).
FIG. 5. Effects of cerebral apoE expression on exploratory behavior.
Active times (A), path lengths (B), as well as time (C) and frequency (D)
of rearing were compared among 6-month-old female wild-type (n 5 14),
knockout (n 5 16), NSE-apoE3 (n 5 6), and NSE-apoE4 (n 5 8) mice
during open field activity. Bar graphs represent results (means 6 SEM)
obtained during the second of three 10-min observation periods. NSE-
apoE4 mice showed mildly reduced active times (A), which differed
significantly only from those observed in wild-type mice (P , 0.05 by
Dunnett’s but insignificant by Tukey–Kramer posthoc test) and knockout
mice (P , 0.05 by Tukey–Kramer posthoc test). ANOVA revealed no
significant differences in pathlengths (B) among the four genotypes.
Compared with wild-type controls, knockout mice and NSE-apoE4 mice
showed significant reductions in frequency (C) and time (D) of rearing
(P , 0.01 by Tukey-Kramer posthoc test), whereas NSE-apoE3 mice did
not (Tukey–Kramer or Dunnett’s posthoc tests).
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was not paralleled by increased exploratory behavior compared
with wild-type controls (Fig. 5 C and D) or by improved swim
speed or capacity to locate the visible platform in the water maze
(Table 1).
Because these tests excluded significant impairments in bal-
ance, strength, or coordination in NSE-apoE4 and knockout
mice, the differences in rearing behavior suggest that vertical
exploratory behavior is impaired in ApoE knockout mice and that
apoE4 cannot compensate for this deficit. These data raise the
intriguing possibility that APOE genotype may also influence
exploratory activity in humans, which could affect learning
performance.
We found no significant differences in rearing times, rearing
events, active times, or path lengths in the open field among
3-month-old female wild-type, knockout, NSE-apoE3, and
NSE-apoE4 mice (data not shown). Therefore, the apoE-
dependent impairments in rearing behavior are also age-
dependent. Compared with age-matched wild-type controls,
6-month-old male NSE-apoE4 and knockout mice displayed
subtler reductions in rearing behavior than females (data not
shown), further indicating that females are more susceptible
than males to apoE-related behavioral impairments.
ApoE-Dependent Neuropathological Alterations. ApoE
knockout mice develop age-dependent neurodegenerative alter-
ations (10), show diminished regenerative capacity after per-
forant pathway lesions (11), and are more susceptible to injury
from focal cerebral ischemia-reperfusion (39). Although these
studies have yielded important insights into potential functions of
murine apoE, they provide no information on the differential
effects of human apoE isoforms on CNS pathobiology. Similarly,
although transgenic mice expressing human apoE isoforms in the
brain have been generated previously (40, 41), these studies did
not determine whether the expression of these molecules had any
effects on CNS integrity or function.
In a recent histopathological comparison of wild-type, knock-
out, NSE-apoE3, and NSE-apoE4 mice (21), we confirmed that
ApoE knockout mice develop an age-dependent loss of synapto-
physin-immunoreactive presynaptic terminals and microtubule-
associated protein-2-positive neuronal dendrites in the neocortex
and hippocampus, two brain structures important for cognitive
function. Expression of apoE3 on the murine ApoE knockout
background prevented this age-related neuronal pathology, but
apoE4 did not. However, NSE-apoE4 mice did not show signif-
icantly more neurodegeneration than age-matched knockout
controls, and there was no difference between male and female
NSE-apoE4 mice with respect to neuronal structure. Therefore,
these structural alterations cannot fully account for the apoE4-
induced functional CNS impairments revealed by the current
study. Additional studies are needed to determine the molecular
mechanisms that underlie apoE4-induced cognitive deficits.
Conclusions. The age- and gender-dependent behavioral
effects of human apoE isoforms identified in our investigation
may be pertinent to cognitive impairments in humans express-
ing apoE4. It is unclear whether cognitive impairments in
human APOE «4 carriers reflect merely the inability of apoE4
to function as well as apoE3 in the CNS or whether apoE4 has
detrimental consequences that go beyond a deficiency in
function. Our study demonstrates that apoE3 can more than
adequately compensate for the lack of murine apoE in the
brain of ApoE knockout mice. In contrast, apoE4 expression
failed to prevent the age-dependent impairments of vertical
exploratory behavior in ApoE knockout mice. Notably, NSE-
apoE4 mice were significantly more impaired in their acqui-
sition of the water maze task than knockout controls, indicat-
ing that the expression of apoE4 is actually worse than having
no apoE at all, consistent with a pathogenic gain-of-function.
Experiments are in progress to determine whether apoE3 or
apoE4 effects predominate in mice expressing both isoforms
on the murine ApoE knockout background.
Although great caution must be applied in extrapolating
from findings in mice to complex human diseases, the results
from these analyses may provide guidance in the decision
whether to pharmacologically inhibit detrimental apoE4 ef-
fects or to simulate apoE3 effects in APOE «4 carriers. The
increased susceptibility of females to apoE4-induced behav-
ioral impairments identified here underlines that interactions
between APOE genotype and gender must be considered
carefully in the design and assessment of AD treatments.
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